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Telomerase is a ribonucleoprotein complex that synthesizes
the G-rich DNA found at the 3-ends of linear chromosomes.
Human telomerase consists minimally of a catalytic protein
(hTERT) and a template-containing RNA (hTR), although other
proteins are involved in regulating telomerase activity in vivo.
Several chaperone proteins, including hsp90 and p23, have
demonstrable roles in establishing telomerase activity both in
vitro and in vivo, and previous reports indicate that hsp90 and
p23 are required for the reconstitution of telomerase activity
from recombinant hTERT and hTR.Herewe report that hTERT
and hTR associate in the absence of a functional hsp90-p23 het-
erocomplex.We also report that hsp90 inhibitors geldanamycin
and novobiocin inhibit recombinant telomerase even after
telomerase is assembled. Inhibition by geldanamycin could be
overcome by allowing telomerase to first bind its primer, sug-
gesting a role for hsp90 in loading telomerase onto the telomere.
Inhibition by novobiocin could not similarly be overcome but
instead resulted in destabilization of the hTERT polypeptide.
We propose that the hsp90-p23 complex fine tunes and stabi-
lizes a functional telomerase structure, allowing primer loading
and extension.
Telomerase is an RNA-dependent DNA polymerase that
extends the 3-ends of linear chromosomes, allowing replicat-
ing cells to overcome the end replication problem (1). The com-
plete subunit composition of the human telomerase ribonucle-
oprotein (RNP)4 complex has yet to be fully elucidated, but the
minimally active enzyme requires the reverse transcriptase cat-
alytic subunit (hTERT) and theRNA subunit (hTR), which con-
tains the template (2–5). Recent findings revealed that chaper-
one proteins, such as hsp90, p23, hsp70, p60, and hsp40/ydj, are
also part of the telomerase RNP, at least during part of the cell
cycle (6, 7). In fact, these chaperones are required to obtain a
functionally active telomerase RNP in vitro, although their pre-
cise role in telomerase assembly remains enigmatic (6, 7).
hsp90 is a highly conserved and abundant protein found in all
eukaryotic cells (8, 9). hsp90 functions as part of a “foldosome”
complex that together with other chaperones facilitates the
accurate arrangement of numerous proteins (10, 11). This
activity is dependent on a number of previously identified func-
tional domains. Important for pharmacological concerns are
the N-terminal ATP-binding site (12, 13) and a putative C-ter-
minal ATP-binding site (14, 15). These sites are essential for
hsp90 function, becauseATPbinding and hydrolysis are crucial
in the conformational regulation of hsp90 and therefore its
effects on client proteins (16). It has been suggested that the two
ATP-binding sites act cooperatively, allowing cross-talk medi-
ated by a central charged domain between the two termini (15).
hsp90 is a functional homodimer with one homodimerization
domain in the C terminus (17) and a second located within the
N terminus (16). There are also a number of co-chaperone
binding domains, including one for the acidic phosphoprotein
p23, which binds to the amino-terminal and central region of
hsp90 in an ATP-dependent manner (13, 18–21) and one for
other co-chaperones (15, 22–25).
The best characterized domain of hsp90 is the highly con-
served, N-terminal, nucleotide-binding pocket (12, 13, 26),
which also serves as the binding site for the hsp90 inhibitor
geldanamycin (GA) (13, 27). GA, a benzoquinone ansamycin
antibiotic, exerts its inhibitory effect by blocking the ATP-de-
pendent binding of p23 to hsp90 (12, 13). Another hsp90 inhib-
itor, the coumarin-type antibiotic novobiocin (NB), binds to
the C terminus of hsp90 and hinders chaperone complex for-
mation by blocking its association with both hsp70 and p23
(15). Due to their antagonizing effects on hsp90 function, both
GA and NB are also inhibitors of proper telomerase assembly
and therefore telomerase activity (6, 28).
The hsp90 client list, which is constantly being updated,
includes various transcription factors, polymerases, signaling
protein kinases, steroid receptors, and other proteins (29).
Besides telomerase, hsp90 has been implicated in activating
another reverse transcriptase (RT), duck hepatitis B virus
(DHBV) RT (30). Interestingly, Hu and Seeger (30) demon-
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strated that the role of hsp90 in DHBV RT activity is to main-
tain the RT in a “protein-priming” conformation capable of
binding to the viral pregenomic RNA, which serves as the tem-
plate for reverse transcription.
In this paper, we further elucidate the role of hsp90 in human
telomerase RNP assembly and function.We show that the addi-
tion of GA or NB to a direct telomerase assay inhibits telomer-
ase activity independent of the order of inhibitor addition (i.e.
before or after telomerase assembly). We also report that
hTERT and hTR are capable of interacting with each other in
the absence of a functional hsp90-p23 complex, although such a
complex is inactive. In these experiments, GA inhibition could
only be overcome if telomerase was preincubated with its
primer. This leads us to propose a model in which the mature
assembly of human telomerase RNP into its final “primer-ac-
cepting” conformation requires hsp90 and its co-chaperones.
hsp90may therefore play a role in human telomerase RNPmat-
uration and ligand binding similar to its role in establishing
active DHBV RT (30) and steroid receptors (31).
EXPERIMENTAL PROCEDURES
Antibodies and Chemical Reagents—The anti-hsp90 mouse
monoclonal antibody (H90–10) was a generous gift from Dr.
David O. Toft (Mayo Clinic, Rochester, MN) (32). GA was pur-
chased from Alexis Biochemicals, and NB was purchased from
MP Biomedicals, Inc. Before use, GA and NB were dissolved in
sterile Me2SO and H2O, respectively.
Reconstitution of Human Telomerase—Wild-type hTR was
in vitro transcribed and purified as previously described (33)
except that the Ampliscribe T7 Transcription Kit was used
(Epicenter Technologies). T7-tagged hTERT was transcribed
and translated from pET-28c-hTERT and the TNT coupled
reticulocyte lysate systems kit (Promega) as previously
described (33). Experiments requiring the visualization of
hTERT utilized protein that was translated in the presence of
[35S]methionine (1175 Ci/mmol, 10 Ci/l; PerkinElmer Life
Sciences). Translation reactions using pET-28c (empty vector
control) were used as a negative control in certain experiments.
Preassembled telomerase was prepared by adding 4 g of in
vitro transcribed hTR to a 400-l reticulocyte lysate reaction
during hTERT translation.
Synthesis of 32P-Labeled RNAs—RNA fragments were gen-
erated using a modification of previously described protocols
(33, 34). Briefly, the DNA template required to transcribe the
pseudoknot domain (hTR nucleotides 46–209) and the CR4-
CR5 domain (hTR nucleotides 243–328) were generated by
PCR. Transcription reactions contained 1 Ampliscribe T7
reaction buffer, 7.5mMCTP, 7.5mMGTP, 7.5mMUTP, 5.8mM
ATP, 0.7 M [-32P]ATP (3000 Ci/mmol, 10 Ci/l;
PerkinElmer Life Sciences), 10 mM dithiothreitol, Ampliscribe
T7 enzyme solution, and the required linear template. Reac-
tions were incubated at 37 °C for 4 h. For full length hTR, ham-
merhead ribozyme cleavage was initiated as described (33).
Reactions were treated with 5 l of RNase-free DNase 1 (1
unit/l; Epicenter), incubated at 37 °C for 20 min, extracted
with phenol/chloroform/isoamyl alcohol, and ethanol-precipi-
tated in the presence of 0.3 MNaOAc. RNAwas resuspended in
10 mM Tris-HCl, 1 mM EDTA, pH 7.5, and unincorporated
[-32P]ATP was removed using a Microspin G-25 column
(Amersham Biosciences).
Synthesis of Biotin-labeled RNAs—A 100-l Ampliscribe T7
transcription reaction contained 1 Ampliscribe T7 reaction
buffer, 7.5 mM GTP, 7.5 mM UTP, 7.5 mM ATP, 6.25 mM CTP,
1.25 mM bio-11-CTP (ENZO Life Sciences), 10 mM dithiothre-
itol, 10 l of Ampliscribe T7 enzyme solution, and the appro-
priateDNA template. Reactionswere incubated for 4 h at 37 °C,
treated with DNase, and purified as described above (33).
Telomerase Assays—Telomerase activity was quantified
using a previously described primer extension assay (33). In
postassembly assays, hTR and hTERT were assembled in the
absence of hsp90 inhibitors, and the primer-extension reaction
included GA or NB. In preassembly assays, hTR and hTERT
were assembled in the presence of GA or NB so that the con-
centration of inhibitor was maintained throughout both the
assembly and primer extension reactions. For each series of
assays, seven data points were used, with GA or NB concentra-
tions ranging from 0 to 5 mM. IC50 values were calculated as
previously described (33).
Association of hTR and hTERT in the Presence of GA andNB—
The ability of hTERT to associate with hTR in the presence of
hsp90 inhibitors was determined using a coimmunoprecipita-
tion assay as described previously with minor modifications
(33). Briefly, 75-l reactions contained T7-tagged [35S]hTERT
(250 fmol) and 80–800 pmol of 32P-labeled pseudoknot or
CR4-CR5 domain or full-length hTR (2.7–3.1  106 cpm/reac-
tion). Inhibition studies also included GA (300 M) or NB (1
mM). Reactions were incubated at 30 °C for 90 min and immu-
noprecipitated using 25l of preblocked anti-T7 antibody-aga-
rose beads (Novagen). Samples were resolved on a 4–12% bis-
Tris SDS gel (Invitrogen) and visualized by phosphorimaging.
The RNA band intensities were normalized to the [35S]hTERT
protein bands and compared with the positive control.
Association of hTR and hTERTWhen GA or NBWas Present
during Translation of hTERT—The association of hTERT with
hTR when hsp90 was inhibited during translation of hTERT
was assayed by affinity purification of full-length hTR using a
modification of a previously described protocol for purification
of human telomerase (35). [35S]hTERT was synthesized in
50-l reactions as described above in the presence of 5 pmol of
hTR and 100 M GA or 1 mM NB. Following a 90-min incuba-
tion at 30 °C, the reactions were combined with 50 l of Ultra-
Link Immobilized NeutrAvidinTM Plus beads (Pierce) and 50
l of buffer A (20 mM Hepes-KOH, pH 7.9, 1 mM EDTA, 300
mM KCl, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
fluoride, 10% glycerol) supplementedwith 0.5%TritonX-100, 5
g of yeast RNA (50 g/ml final concentration), and 100 pmol
of hTRbait, an affinity oligonucleotide complementary to the
template of hTR (5-biotin-CTAGACCTGTCATCAmGm-
UmUmAmGmGmGmUmUmAmG-3 where m represents
2-O-methyl ribose). Before use, the beads were washed once
with 300 l of buffer A, blocked twice with 250 l of blocking
buffer (buffer A supplemented with 0.5 mg/ml bovine serum
albumin) for 15 min at 4 °C, and then washed with 300 l of
buffer A. The beads were precipitated by centrifugation at
2500  g for 1.5 min. The reactions were then incubated for 10
min at room temperature, followed by 2 h at 4 °C on a rotary
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platform. The resulting bead complexes were washed three
times with 300 l of buffer A supplemented with 0.5% Triton
X-100, once with 300l of buffer A supplementedwith 300mM
KCl, and twice with buffer A alone. Samples were resolved by
SDS-PAGE and visualized by phosphorimaging. [35S]hTERT
was normalized to inputs and compared with the positive con-
trol. Controls containing Me2SO and H2O were conducted for
comparison with GA and NB, respectively. The association of
the CR4-CR5 and pseudoknot domains of hTR with hTERT
was determined using biotin-labeled RNA. [35S]hTERT was
synthesized in 50-l reactions as described above in the pres-
ence of 60 pmol of the biotinylated pseudoknot domain or
biotinylated CR4-CR5 domain and 100 M GA or Me2SO car-
rier. Each reaction was then affinity-purified with 45 l of pre-
blocked MPG Streptavidin beads (Pure Biotech, LLC). Beads
were washed four times with 400 l of wash buffer 1 and
blocked twice with 250 l of blocking buffer for 15 min at 4 °C
before use. The beads were precipitated by centrifugation at
2500  g for 2 min between each step. Each 50-l reaction was
then mixed with 50 l of blocking buffer and centrifuged at
17,000  g for 10 min at 4 °C in order to remove any precipi-
tates. The supernatant was added to the blocked beads, and the
samples were incubated for 45 min at room temperature on a
rotary platform. The resulting bead complexes were washed
three times with 350 l of buffer A and once with 350 l of
TMG. The precipitated bead samples were analyzed by SDS-
PAGE as described above.
Immunoprecipitation with an hsp90 Antibody—Preassembled
telomerase complexes were immunoprecipitated using a previ-
ously described protocol (6). Briefly, 75 l of telomerase preas-
sembled with [35S]hTERT was incubated at 30 °C in the presence
of 1gofhuman telomericprimer, no telomericprimer, or 1gof
nontelomeric primer. After 90 min, anti-hsp90 mouse mono-
clonal antibody (H90–10) was added to a final concentration of
0.5 g/ml, and the samples were placed on ice for 1 h. Each
reaction was immunoprecipitated by the addition of 22.5 l of
prewashed Protein G-agarose beads (Roche Applied Sciences)
and was incubated at 4 °C for 1 h with constant rotation. The
beads were thenwashed three times with 400l ofWash Buffer
(20 mM Hepes, pH 7.6, 20% glycerol, 100 mM NaCl, 0.2 mM
EGTA, 1 mM MgCl2, 0.1% Nonidet P-40, 0.1% bovine serum
albumin). The precipitated bead samples were analyzed by
SDS-PAGE as described above.
Lys-C Proteolysis of hTERT—The stability of hTERT was
determined by Lys-C proteolysis using a modification of a pre-
viously described protocol (36). 700 fmol of T7-tagged
[35S]hTERT and 3g of hTRwere allowed to assemble either in
the presence or absence of 100 M GA or 1 mM NB at 30 °C for
90 min. Each reaction was then immunoprecipitated using 30
l of preblocked anti-T7 antibody-agarose beads (Novagen), as
previously described (33). Following immunoprecipitation, the
beads were washed with and resuspended in 80 l of digestion
buffer (25mMTris-HCl, pH 8.5, 1mMEDTA). Each sample was
then treated with90 ng of endoproteinase Lys-C (sequencing
grade; Roche Applied Science) and was incubated at 30 °C. Ali-
quots of each reaction were removed at various time points and
quenched with an equal volume of Laemmli sample buffer (125
mM Tris-Cl, pH 6.8, 4% SDS, 0.005% bromphenol blue, 20%
glycerol, 0.72 M -mercaptoethanol) followed by heating at
95 °C for 5 min. Samples were resolved on a 4–12% bis-Tris
SDS gel (Invitrogen) and visualized by phosphorimaging.
RESULTS
hsp90 Inhibitors Affect in Vitro Reconstituted Human Telom-
erase Activity both Before and After Assembly—To examine the
role of hsp90 in telomerase activation, we used two hsp90
inhibitors: GA, which binds to the N-terminal ATP-binding
site, andNB,which binds to the putativeC-terminal ATP-bind-
ing site. Despite their separate binding sites, both compounds
have been reported to inhibit human telomerase (6, 28). In our
hands, GA inhibited the in vitro reconstitution of telomerase
activity when added before assembly with an IC50pre value of
8.4  3.7 M, and NB inhibited with an IC50pre of 148  18 M
(Fig. 1). Notably, the concentrations of GA and NB were main-
tained throughout the assays, including both the assembly and
the primer extension reactions. These findings are consistent
with the hypothesis that hsp90 inhibitors exert their effect by
preventing hsp90-dependent association between hTR and
hTERT.We further tested the role of hsp90 by adding the hsp90
inhibitors to telomerase that was preassembled. Surprisingly,
we found that both GA and NB inhibited telomerase activity
and found IC50post values of 53 7 and 408 50M, respectively,
FIGURE 1. GA and NB inhibit telomerase when added before or after
assembly. A, concentration dependence of GA on telomerase activity in an
assembly assay (preassembly; f) and a direct assay (postassembly; Œ). B, con-
centration dependence of NB on telomerase activity in an assembly assay and
a direct assay. Error bars, S.D. (n  4).
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for these drugs (Fig. 1). Although the IC50 values forGA andNB
were slightly higher when added postassembly as compared
with their addition preassembly, both drugs were full antago-
nists of assembled telomerase. We found that the addition of
p23 partially suppressed inhibition by GA, so its effects are
unlikely to be a direct effect on telomerase (Fig. 2).
TelomeraseMaintains hTR-hTERT Interactions in the Presence
of Geldanamycin and Novobiocin after hTERT Translation—
hsp90 was previously shown to be required for reconstituting
active recombinant telomerase and to be involved in maintaining
telomeraseactivity inculturedhumancells (6, 37).Theprecise role
of hsp90 in establishing active telomerase, however, is not clear
from these studies. To determine if hsp90 is involved in establish-
ing the association of hTR and hTERT during telomerase assem-
bly, we performed co-immunoprecipitation assays using
T7-tagged [35S]hTERT and [32P]RNA in the presence of 300 M
GA or 1 mM NB. We tested the ability of GA and NB to inhibit
hTERT binding to full-length hTR as well as the CR4-CR5 and
pseudoknot domains, which are two regions of hTR previously
shownto interact independentlywithhTERT(33,34,38–40).The
CR4-CR5domain is a structurally conserveddomain found in ver-
tebrate telomeraseRNAs. Inhumans, theCR4-CR5domain iswell
defined and contains a stem-loop termed p6.1, whose direct inter-
actionwithhTERT is required for telomerase activity (34, 38–40).
The pseudoknot domain, which contains the template, also inde-
pendently binds hTERT (39, 40). We found that hsp90 inhibition
does not affect the association of hTERT with hTR or the two
domains of hTRwe tested (Fig. 3A). This suggests that hsp90 does
not facilitate the associationof hTRandhTERT.Clearly, however,
the telomerase complex that is assembledwhen hsp90 is inhibited
is dysfunctional.
hsp90 and other chaperones function in part to stabilize pep-
tides during translation to prevent improper folding (41). In the
previous experiments, GA and NB were added after hTERT had
been translated,while hsp90waspresumably active.Todetermine
if hsp90 activity is required to allow the nascent hTERT transcript
to assume an hTR binding-competent state, we inhibited hsp90
during hTERT translation. Because inhibition of hsp90 during
translation appeared to affect immunoprecipitation efficiency in
preliminary studies, we used affinity purification of the RNA sub-
unit to assess hTR-hTERT association. To analyze the association
of full-length hTRwith hTERT, telomerase complexes were affin-
ity-purifiedusing abiotinylatedoligo-
nucleotide that was complementary
to the RNA template (35). To analyze
the association of the CR4-CR5 and
pseudoknot domains with hTERT,
[35S]hTERT was translated in the
presence of biotin-labeled RNAs and
GA (33). Interestingly, only the inter-
action of the CR4-CR5 domain was
dramatically affected by the presence
ofGAduring hTERT translation (Fig.
3B, lanes 3 and 4), although there was
a small decrease in the amount of
pseudoknot domain that co-purified
with hTERT (Fig. 3B, lanes 1 and 2).
The interaction between hTERT and
full-length hTR was not affected by
thepresenceofGAduring translation
(Fig. 3B, lanes 5 and 6). NB, on the
otherhand,was found topreventover
60% of the full-length hTR/hTERT
interaction when present during
translation (Fig. 3B, lanes 7 and 8).
Primer Binding Overcomes GA,
but Not NB, Inhibition of Human
Telomerase—If GA does not affect
telomerase by preventing the asso-
FIGURE 2. p23 partially rescues GA-induced telomerase inhibition. Telom-
erase activity was inhibited in an assembly assay by the addition of 75 M GA
(lanes 2 and 3). p23 was added to the reaction prior to assembly at a final
concentration of 20 M (lane 3). Error bars, S.D. (n  6).
FIGURE 3. hTR/hTERT interactions are unaffected by the presence of GA and NB after translation of
hTERT, but hTR/hTERT interactions are affected by the presence of GA and NB during translation. A,
32P-labeled pseudoknot domain (lanes 1–3), 32P-labeled CR4-CR5 domain (lanes 4 – 6), or 32P-labeled full-length
hTR (lanes 7–9) was incubated with T7-tagged [35S]hTERT either in the presence or absence of 300 M GA or 1
mM NB. B, pseudoknot domain (lanes 1 and 2), CR4-CR5 domain (lanes 3 and 4), or full-length hTR (lanes 5– 8)
were incubated with T7-tagged [35S]hTERT and 100 M GA or 1 mM NB. The complexes were affinity-purified
and resolved on an SDS gel. % Bound values indicate the amount of protein bound to the RNA when compared
with control reactions with no GA or NB. Gels shown are representative of multiple (2– 4) experiments. Inde-
pendent experiments revealed no significant nonspecific binding (5%).
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ciation of hTR with properly translated hTERT, then how does
it inhibit its enzymatic activity? One possibility is that hsp90 is
involved in loading telomerase onto the chromosome end (i.e.
hsp90 might be involved in telomerase-primer docking). Hu
and Seeger (30) found that hsp90 maintains the DHBV RT in a
“protein-priming” conformation capable of binding the RNA
template used for reverse transcription. Similarly, hsp90 pro-
motes binding of steroid receptor complexes to their ligands
(31, 42–44). Thus, it seems that hsp90 can participate in pre-
paring its clients for substrate and ligand binding. Based on this
precedent, we determined if hsp90 plays a direct role in telom-
erase-primer loading.
We performed direct extension assays in the presence of
either GA or NB and telomerase or telomerase preincubated
with a telomeric primer.We found that preincubation of a telo-
meric primer with telomerase overcame GA-induced inhibi-
tion (Fig. 4, A and B). This effect was dependent on a telomeric
primer, since a nontelomeric primer did not elicit the rescue
effect (Fig. 4,A and B, lane 4). Because NB, like GA, is an hsp90
inhibitor, we would expect to see a similar rescue effect. Sur-
prisingly, preincubation of a telomeric primer with telomerase
did not overcomeNB inhibition (Fig. 3,C andD). This suggests
that the two drug-binding sites separate two different telomer-
ase-specific functions of hsp90.
hsp90 Is Associated with hTERT after Telomeric Primer
Binding—If hsp90 is involved in primer loading, then it might
be expected to release the telomerase complex once docking
has occurred, similar to the behavior of hsp90 in facilitating
ligand binding to steroid receptors (31). To test this possibility,
we examined the association of [35S]hTERT with hsp90 in the
presence or absence of a telomeric primer. The holoenzyme
complexeswere preincubatedwith a telomeric primer or a non-
FIGURE 4. Preincubation with primer rescues GA-induced but not NB-induced telomerase inhibition. Preassembled telomerase was assayed for activity
in the absence (lane 1) or presence (lanes 2– 4) of GA (A) or NB (C). Preassembled telomerase was preincubated with primer (Primer pre-inc), followed by the
addition of GA or NB (A and C, lanes 3 and 4). Lane 3 included a telomeric primer, whereas lane 4 included a nontelomeric primer. Quantified telomerase activity
is displayed in B and D. % Activity is the amount of residual telomerase activity when compared with the positive control (lane 1). The 32P loading control (L.C.)
and the human telomere primer-extension products (4, 10, 16, 22, etc. nucleotides added) are indicated. The lane numbers for B and D correlate with
A and C, respectively. Error bars, S.D (n  3).
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telomeric primer or in the absence of added DNA. The result-
ing complexes were immunoprecipitated with an anti-hsp90
antibody. We found that the presence of the telomeric primer
had no significant effect on the interaction between hsp90 and
hTERT when compared with the positive control without
primer (Fig. 5). Similarly, a nontelomeric primer, which served
as a control for specificity, exhibited little effect (Fig. 5, lane 3).
This result is consistent with a previous report that demon-
strated the association of hsp90 with active human telomerase
(6). A negative control with no primer or antibody yielded8%
nonspecific binding of [35S]hTERT to the beads (Fig. 5, lane 4).
hsp90 Inhibition Alters hTERT Stability—One possible
explanation for the effects of GA and NB on telomerase is that
hsp90 is involved in stabilizing hTERT and therefore the telom-
erase complex. For example, hTERT stability or its conforma-
tion could depend on hsp90 activity. We used partial proteoly-
sis to examine the global structure of hTERT. Partial proteolysis
is a powerful technique used to identify substructures and func-
tional domains in various proteins (45) and has been used to
examine the global structure of Tetrahymena thermophila
TERTmutants (36). To determine if GA and NB affect hTERT
stability, we treated hsp90-inhibited assembly reactions with
Lys-C, an endoproteinase that cleaves at K–X bonds, and deter-
mined the rate of proteolysis in the absence and presence of
hsp90 inhibitors. In the absence of hsp90 inhibitors, hTERT
degraded with a half-life of 15 min (Fig. 6). Further, several
prominent hTERT digestion products were observed. In the
presence of GA, the hTERT half-life was similar, and the same
degradation banding pattern was observed. In contrast, we
found that NB significantly affected the rate of full-length
hTERT proteolysis by decreasing the half-life to 5 min. The
most obvious difference in hTERT degradation between NB
and its control is seen at the earliest time point, at which there
is 100% hTERT remaining in the control reaction but only
50% left whenNB is present (Fig. 5, compare lane 10with lane
14). Furthermore, when comparing the amounts of truncated
proteolysis products at the 60-min time point, the NB-treated
sample has a significantly decreased level of products when
compared with both the H2O control and the GA-treated sam-
ple (Fig. 6, compare lane 16 with lanes 8 and 12). This presum-
ably resulted from increased Lys-C digestion of the already
truncated proteolysis products due to decreased hTERT stabil-
ity. Further experiments are needed to determine precisely
what domains of hTERT have become vulnerable to proteoly-
sis. The increase in Lys-C degradation in the presence of NB,
but not GA, may explain why primer binding does not over-
come NB inhibition.
A possible consequence of decreased hTERT stability is a
commensurate decrease in telomerase complex stability. Using
a pulse-chase experiment, we determined if telomerase stability
was affected by GA or NB by examining the dissociation rate of
the CR4-CR5 and pseudoknot domains from hTERT. We did
not detect any change in the dissociation rate of the RNA-pro-
tein complexes in our assay (Fig. S1). However, we consistently
observed a time-dependent decrease in the ability to immuno-
precipitate hTERT in the presence of NB as compared with the
positive control. GA also had a slight effect on immunoprecipi-
tation, although the effect was much less severe than the NB
effect. These results are consistent with the conclusion that NB
destabilizes hTERT.
hsp90 Is Associated with hTERT following Geldanamycin or
NovobiocinTreatment—Yun et al. (46) showed thatNBbinding
to hsp90 induces a conformational change that induces disso-
ciation from client proteins. They specifically showed that this
“client release” conformation promotes the dissociation of
hsp90 from the heme-regulated eIF2 kinase. A similar phe-
nomenon would explain our finding that NB caused increased
Lys-C proteolysis of hTERT and explainwhy preloading primer
does not overcome NB inhibition. Previously, Holt et al. (6)
showed that GA has no effect on hsp90/hTERT interaction.
Using an anti-hsp90 antibody to co-immunoprecipitate
[35S]hTERT, we confirm that GA does not affect the hsp90/
hTERT interaction and report that NB caused no decrease in
the co-immunoprecipitation efficiency of hTERT with hsp90,
even at a concentration that caused 80% inhibition in telomer-
ase activity (Fig. S2). Apparently, NB-induced dissociation of
hsp90 from its clients is dependent on the particular client, and
hTERT remains bound to hsp90 even in the presence of NB.
DISCUSSION
Human telomerase must be properly assembled to produce
an active complex. The biogenesis of telomerase has received
much attention and appears to be a complex process that
requires specific pathways for maturation of its RNA subunit
(47, 48) as well as assembly of the holoenzyme complex (6, 7,
49). It was previously revealed that the hsp90 chaperone com-
plex interacts with hTERT and that hsp90 activity is required
for establishing active telomerase in both in vitro reconstitution
assays and cultured human cells. In this work, we set out to
further expand our understanding of the biochemical role of
hsp90 in maintaining telomerase activity, and we have estab-
lished that the role of hsp90 in activating telomerase is more
complex than previously thought.
We confirmed that hsp90 inhibitors GA and NB prevent
reconstitution of active human telomerase (Fig. 1). Surpris-
ingly, we found that this inhibition was not the result of pre-
venting the association of hTERTwith hTR or specific domains
of hTR (Fig. 3A). On the contrary, we found that hTR and
hTERT are capable of interacting in the presence of either GA
FIGURE 5. hsp90 remains associated with hTERT after primer loading.
35S-Labeled telomerase was incubated alone (lane 1), in the presence of telo-
meric primer (lane 2), or in the presence of nontelomeric primer (lane 3) and
immunopurified with an hsp90 antibody. % Bound values indicate the
amount of 35S-labeled telomerase bound to hsp90 when compared with the
positive control (lane 1). All immunoprecipitations were performed in dupli-
cate, and representative results are shown.
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orNB, although the RNP complex that is assembled in the pres-
ence of these hsp90 inhibitors is inactive. Interestingly, when
added to an assembly reaction prior to translation of the hTERT
gene, NB caused a decrease in the amount of hTERT that co-
immunoprecipitated with full-length hTR, whereas GA only
affected the association of the CR4-CR5 domain with hTERT
(Fig. 3B). This suggests that the nascent hTERT transcript
requires hsp90 activity to achieve a structure that is fully com-
petent in hTR binding and that the NB-targeted C terminus of
hsp90 may be more important in maintaining polypeptide sta-
bility than the GA-targeted N terminus. In summary, our
results indicate that hsp90 does not chaperone the marriage of
hTERT to hTR, per se, but may instead be involved in ensuring
that nascent hTERT folds properly and in fine tuning andmain-
taining the structure of the assembled telomerase complex.
When GA or NB was added to preassembled telomerase, we
observed complete inhibition of telomerase activity, albeit with
a higher IC50 than when the inhibitors were added before
assembly (Fig. 1). There are several possible explanations for
this result. During early work on the mechanism of GA action,
it was noted that GA is an inhibitor of several nucleotide trans-
ferases, including DNA pol  (50), although it is not clear from
these studies if the effect is related to hsp90 inhibition or spe-
cific polymerase inhibition. More recently, it was found that
whereas GA inhibits hepatitis B RT, it does so by binding hsp90
and is not an RT inhibitor, since GA inhibition could be over-
come using a synthetic mutant that was hsp90-independent
(30, 51). Although we cannot entirely rule out direct inhibition
of telomerase byGA andNB, the history ofGA andNB suggests
that hsp90 is the more likely candidate in our studies. Several
observations are consistent with this conclusion. First, GA and
NB have different effects on telomerase and are known to bind
two distinct sites on hsp90 that have distinct functions in the
hsp90 reaction cycle. Furthermore, the addition of p23, which
has an overlapping binding site with GA, partially rescued
telomerase activity fromGA inhibition (Fig. 2).We also showed
thatNBaffects the stability of hTERT, consistentwith anhsp90-
dependent activity. Together, the known pharmacological
effects of GA and NB on hsp90 and the observations we
describe here are more consistent with an effect on hsp90 than
a direct inhibitory effect on telomerase.
Since hsp90 does not seem to be explicitly required to pro-
mote the association of hTERT and hTR, we speculated that it
might be involved in primer loading. This hypothesis was based
on work with DHBV RT, for which hsp90 removes an autoin-
hibitory domain away from the RT active site to allow primer
loading and RNA binding (30, 51). We found that preincuba-
tion of a telomerase primer with preassembled telomerase,
prior to the addition of GA, rescued GA-induced telomerase
inhibition (Fig. 4, A and B). However, preincubation with
primer did not overcome NB-induced telomerase inhibition
(Fig. 4, C and D). Although it has been suggested that the two
termini of hsp90 engage in cooperativity and cross-talk (15),
our results indicate that GA and NB dissociate different facets
FIGURE 6. NB, but not GA, increases the proteolysis rate of hTERT. [35S]hTERT and hTR were assembled in the presence or absence of hsp90 inhibitors.
Following co-immunopurification, the complexes were digested with Lys-C, and aliquots were quenched at the indicated time points. [35S]hTERT fragments
digested after GA (A) or NB (C ) treatment were resolved by SDS-PAGE. The amount of full-length [35S]hTERT proteolysis is displayed in B and D. Error bars, S.D.
(n  2). DMSO, dimethyl sulfoxide.
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of hsp90 involvement with telomerase and implicate different
functions of the N- and C-terminal hsp90 domains in the
telomerase reaction cycle. hsp90 appears to be directly involved
in primer loading and in stabilizing the active telomerase com-
plex as shown in the model presented in Fig. 7. In this model,
the N-terminal ATP binding site functions to maintain telom-
erase in a primer-binding state. The role of the putative C-ter-
minal ATP binding site is to confer hsp90-dependent stability
to hTERT. This proposal is consistent with the apparent insta-
bility of hTERT in the presence of NB and the rescue of GA
inhibition by primer. Furthermore, although GA andNB target
different ligand-binding sites on hsp90, they both displace p23
from hsp90 (12, 13, 15). This suggests that p23 displacement is
not related to primer binding.
Unlike the transient nature of some chaperones and client
proteins, it is clear from our studies and those of the Holt lab-
oratory (7) that hsp90 is stably associated with the telomerase
holoenzyme both after hTERT/hTR assembly and after primer
binding (Fig. 5). To explain this, we propose that hsp90 remains
bound to hTERT in order to maintain the holoenzyme in a
conformation capable of primer binding and catalysis (Fig. 7).
By comparison with the DHBV holoenzyme (51), perhaps one
role of hsp90 in telomerase holoenzyme maturation may
include the manipulation and offsetting of an autoinhibitory
domain to allow primer loading. It is not clear if hTERT con-
tains an autoinhibitory domain, but it is clear that the presence
of functional hsp90 does allow for efficient primer binding and
thus increased telomerase activity. Further studies using trun-
cated hTERT mutants will address the existence of an hsp90-
antagonized autoinhibitory domain on hTERT.
The mechanism of hsp90-targeted inhibition of telomer-
ase in cells appears more complex.
Antisense oligonucleotides target-
ing cellular hsp90 have been
shown to directly reduce hsp90
mRNA expression and decrease
telomerase activity (52). However,
hsp90 plays a significant role in
regulating many cellular signaling
pathways, including that for the
serine/threonine kinase Akt. Akt
has been found to increase human
telomerase activity via phospho-
rylation of hTERT (53). The asso-
ciation with hsp90 is required to
maintain Akt in an active state (54),
and GA- and NB-mediated hsp90
inhibition has been found to inhibit
the Akt cascade (28, 55), thus lead-
ing to decreased telomerase activity.
Furthermore, GA-induced hsp90
inhibition inH1299 cells leads to the
ubiquitination and proteosome-
mediated degradation of hTERT
(56). These indirect effects on
telomerase activity must therefore
be taken into account when eluci-
dating the cellular mechanisms of
GA- and NB-induced telomerase inhibition.
In conclusion, we have found that the role of hsp90 in the
telomerase reaction cycle is more complex than expected.
hsp90 is not specifically involved in allowing hTR to bind
hTERT, although it appears to be involved in fine tuning and
stabilizing the structure of the telomerase complex. Active
hsp90 seems to be required both during translation of the nas-
cent hTERT transcript and for the assembly of active telomer-
ase. Importantly, hsp90 appears to be involved in maintaining
telomerase in a conformation that is competent to bind the
telomere. Although it remains to be seen if this is true in vivo, it
is an attractive model for allowing the hsp90-dependent regu-
lation of telomerase and is consistent with the role of hsp90 in
facilitating ligand binding to other hsp90 clients.
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